论文部分内容阅读
目的:探讨Ⅱ型糖尿病血管病变与纤溶酶原激活剂抑制物(PAI-1)之间的关系。方法:选取46例正常人,71例Ⅱ型糖尿病患者,采用酶联免疫吸附法(ELISA)测定其纤溶酶原激活剂抑制物(PAI-1)水平。结果:无并发症糖尿病组(NOMIMA组)与正常对照组比,PAI-1无显著性差异,并发血管病变各组,PAI-1高于正常对照组,合并大血管病变组(MA组)的PAI-1比NOMIMA组升高,差异显著;合并微血管病变组(MI组)与NOMIMA组比,PAI-1有升高趋势,但差异不显著(P=0.0676);简单相关分析显示PAI-1与体重指数(BMI)(γ=0.31,P<0.05)、空腹胰岛素(InsO)(γ=0.20,P<0.05)呈正相关。多元回归分析显示BMI、InsO作为独立的因素影响PAI-1水平(β_1=0.32,P<0.05,β_2=0.46,P<0.05)。结论:Ⅱ型糖尿病合并血管病变者PAI-1水平升高,PAI-1水平可能与肥胖及胰岛素水平有关。
Objective: To investigate the relationship between type 2 diabetic vascular lesions and plasminogen activator inhibitor (PAI-1). Methods: Forty-six healthy subjects and 71 patients with type 2 diabetes were enrolled in this study. PAI-1 level was measured by ELISA. Results: Compared with the normal control group, there was no significant difference in PAI-1 between the non-complication diabetic group (NOMIMA group) and the normal control group. PAI-1 was higher in all the groups with vascular lesion than in the normal control group and in the macrovascular disease group (MA group) Compared with NOMIMA group, the PAI-1 level in PAH-1 group was significantly higher than that in NOMIMA group (P = 0.0676); PAI-1 was increased in MI group compared with NOMIMA group It was positively correlated with body mass index (BMI) (γ = 0.31, P <0.05) and fasting insulin (γ = 0.20, P <0.05). Multiple regression analysis showed that BMI and InsO influenced PAI-1 levels as independent factors (β_1 = 0.32, P <0.05, β_2 = 0.46, P <0.05). Conclusion: The PAI-1 level in patients with type 2 diabetes mellitus complicated with vascular lesions is elevated. The level of PAI-1 may be related to obesity and insulin levels.